Latest Breaking News On - Nephrol dial - Page 1 : comparemela.com

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label.

Czech republicUnited statesParag mahantiDavid soergelPrnewswire novartisMarianne silkjMarlena abdinoorJonathan grahamDavid kavanaghSloan simpsonFaculty of medical sciences at newcastle universityUniversity of washingtonG steering committee memberMetabolism development unitEuropean renal associationNovartis pharmaceuticals corporation

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%.

United statesJonathan grahamMarlena abdinoorSloan simpsonLoreto mdaParag mahantiLambers heerspinkBartonm endothelinMichael meoNovartis fabhaltaPrnewswire novartisEuropean renal associationFibrotic transcriptional networksNovartis pharmaceuticals corporationExchange commissionEndpoint analysis

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesCzech republicImke kappesJonathan grahamMarlena abdinoorDavid kavanaghNicole zinsli sommParag mahantiMarianne silkjSatoshi sugimotoDavid soergelIsabella zinckSloan simpsonMichael meoExchange commissionUniversity of washington

Novartis atrasentan Phase III data show clinically

Novartis atrasentan Phase III data show clinically
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLambers heerspinkSloan simpsonMichael meoSatoshi sugimotoJonathan grahamImke kappesMarlena abdinoorLoreto mdaBartonm endothelinNicole zinsli sommParag mahantiIsabella zinckNovartis fabhaltaEuropean renal associationExchange commission

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.

United statesSloan simpsonNicole zinsli sommLambers heerspinkJonathan grahamSatoshi sugimotoParag mahantiMarlena abdinoorImke kappesIsabella zinckNovartis fabhaltaMichael meoLoreto mdaBartonm endothelinExchange commissionEuropean renal association